Document text
Principal Investigator: Patrizia Farci
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $47,482
Funding agency: National Institute of Allergy and Infectious Diseases
Screening of more than 120 convalescent patients from COVID-19, recruited at the NIH Blood Bank, identified 15 sera with high titers of neutralizing antibodies against SARS-CoV-2. Whole blood from these 15 donors was processed (isolation of PBMCs, B-cell purification, extraction of mRNA, cDNA synthesis, and PCR amplification of VH, VK and VL genes) and 4 antibody phage-display libraries were constructed from isolated B-cell RNA. All 4 libraries were panned against the recombinant trimeric S protein of SARS-CoV-2, which has led so far to the identification of 612 positive clones that specifically bind to the S protein. Sequence analysis identified 18 distinct clones. The selected monoclonal antibodies have been functionally characterized by ELISA and affinity measurement by using surface plasmon resonance (SPR), followed by expression of Fabs as full-length IgG. Determination of the neutralizing activity against SARS-CoV2 was initially performed using a pseudovirus-based assay system and then a neutralization assay with the entire virus. Binding affinity of the 18 Fabs by SPR showed that their affinity was extremely high in all, with most of them in the picomolar range. Full-length IgG were used for testing their neutralizing activity. We found that several antibodies potently neutralized the wild-type variant (WA1-2020), as well as the South African variant (B.1.351), the UK variant (B.1.1.7) and the delta variant (B.1.1.7). The neutralizing activity of our monoclonal antibodies was also confirmed using live virus against the wild-type variant, the South African variant, and the UK variant. Studies in the animal model using golden Syrian hamsters are in progress to determine the prophylactic and therapeutic activity of our monoclonal antibodies.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><7S Gamma Globulin><ARDS><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Affinity><Animal Model><Animal Models and Related Studies><Antibodies><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><B.1.1.7><B.1.351><B.1.617.2><Binding><Bioassay><Biologic Assays><Biological Assay><Blood Banks><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19 antibody><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 long hauler><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><Cessation of life><Clinical Treatment Moab><CoV-2><CoV2><Complementary DNA><Country><Da Nang Lung><Death><Delta variant><Disease><Disorder><ELISA><Enzyme-Linked Immunosorbent Assay><Generations><Genes><Genetic Alteration><Genetic Change><Genetic defect><Goals><Golden Hamsters><Golden Syrian Hamsters><IgG><Immunoglobulin G><Length><Libraries><Measurement><Mesocricetus auratus><Messenger RNA><Molecular Interaction><Monoclonal Antibodies><Mutation><NIH><National Institutes of Health><Non-Polyadenylated RNA><PBMC><Peripheral Blood Mononuclear Cell><Phage Display><Prevention therapy><Process><Proteins><RNA><RNA Gene Products><RNA Viruses><Recombinants><Ribonucleic Acid><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 B.1.351><SARS-CoV-2 B.1.617.2><SARS-CoV-2 antibody><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SEQ-AN><Sequence Analyses><Sequence Analysis><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Shock Lung><South Africa variant><South African variant><Stiff lung><Surface Plasmon Resonance><Symptoms><Syrian Hamsters><System><Testing><Therapeutic><Time><U.K. variant><UK variant><United Kingdom variant><United States><United States National Institutes of Health><Variant><Variation><Virus><Whole Blood><Wuhan coronavirus><access to vaccination><access to vaccines><anti-viral agents><anti-viral drugs><anti-virals><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><cDNA><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 long hauler><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus patient><disease severity><genome mutation><hCoV19><long hauler><mAbs><mRNA><model of animal><model organism><nCoV2><neutralizing antibody><neutralizing mAb><neutralizing monoclonal antibodies><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><prophylactic><recruit><screening><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><vaccination access><vaccination availability><vaccine access><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine availability><vaccine for novel coronavirus><wet lung>